Mesoblast (MESO) Reports Q1 Loss of $0.04/Share

Go back to Mesoblast (MESO) Reports Q1 Loss of $0.04/Share

Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results

December 16, 2015 4:57 PM EST

Materially Strengthened Cash Reserves

First Royalties From TEMCELL Product Sales Expected In Q1 2016

Resources Prioritized On Tier 1 Product Candidates

Cash Managed To Extend Runway And Achieve Tier 1 Value Inflexion Points

Major Focus Is FDA Filing For Our First US Product Approval In Acute Graft Versus Host Disease

MELBOURNE, Australia; and NEW YORK, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:... More

Mesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015

December 15, 2015 7:52 PM EST

MELBOURNE, Australia and NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB) (Nasdaq: MESO) today announced it will report financial results for the quarter ended 30 September 2015 after the close of the Nasdaq market on Wednesday 16 December. Mesoblast management will host a conference call to review results and provide a corporate update beginning at 5:00 pm Eastern Time on... More